US contractor upholds Pacific Edge's Medicare ban

US contractor upholds Pacific Edge's Medicare ban
Pacific Edge has had a fresh blow to its hopes for access to the US Medicare market for Cxbladder diagnostic tests. (Image: Pacific Edge)
Greg Hurrell
Pacific Edge’s flagship Cxbladder cancer testing has been deemed as “not considered medically reasonable and necessary” by the company’s United States Medicare administrator. The statement is in a new proposed Local Coverage Determination (LCD) for Medicare and is a fresh blow for the company’s hopes to quickly regain long-term access to the Medicare system for its bladder cancer tests.Medicare is Pacific Edge’s largest customer.The new LCD was released overnight New Zealand time by Novitas, Pacific Edge...

More Markets

NZ stocks end firm after Sky, Vulcan, annual meetings
Markets Market Close

NZ stocks end firm after Sky, Vulcan, annual meetings

There were 84 rises and 54 falls on the main board.

Jamie Gray 31 Oct 2025
Rising volumes push Port of Tauranga profit outlook higher
Primary Sector

Rising volumes push Port of Tauranga profit outlook higher

Port of Tauranga expects its full-year net profit after tax to fall somewhere between $137 million and $147m.The NZX-listed port company’s container volumes increased 9% to 319,649 TEUs in the first three months to Sept 30.Total trade increased 5.9% in volume compared to the same...

Staff reporters 31 Oct 2025
SkyCity faces Adelaide reckoning by year-end
Markets

SkyCity faces Adelaide reckoning by year-end

Casino operator releases details about regulatory situation in Adelaide.

Dileepa Fonseka 31 Oct 2025